| PHY906 (KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment W Lam, Z Jiang, F Guan, X Huang, R Hu, J Wang, S Bussom, SH Liu, ... Scientific reports 5 (1), 9384, 2015 | 119 | 2015 |
| Transcriptional profiles from paired normal samples offer complementary information on cancer patient survival–evidence from TCGA pan-cancer data X Huang, DF Stern, H Zhao Scientific reports 6 (1), 20567, 2016 | 95 | 2016 |
| Dual MAPK inhibition is an effective therapeutic strategy for a subset of class II BRAF mutant melanomas M Dankner, M Lajoie, D Moldoveanu, TT Nguyen, P Savage, S Rajkumar, ... Clinical Cancer Research 24 (24), 6483-6494, 2018 | 71 | 2018 |
| Inferring functional interaction and transition patterns via dynamic Bayesian variable partition models J Zhang, X Li, C Li, Z Lian, X Huang, G Zhong, D Zhu, K Li, C Jin, X Hu, ... Human brain mapping 35 (7), 3314-3331, 2014 | 48 | 2014 |
| Inferring consistent functional interaction patterns from natural stimulus FMRI data J Sun, X Hu, X Huang, Y Liu, K Li, X Li, J Han, L Guo, T Liu, J Zhang NeuroImage 61 (4), 987-999, 2012 | 40 | 2012 |
| Risankizumab versus ustekinumab for moderate-to-severe Crohn’s disease L Peyrin-Biroulet, JC Chapman, JF Colombel, F Caprioli, G D’Haens, ... New England Journal of Medicine 391 (3), 213-223, 2024 | 26 | 2024 |
| The discovery of novel protein-coding features in mouse genome based on mass spectrometry data XB Xing, QR Li, H Sun, X Fu, F Zhan, X Huang, J Li, CL Chen, Y Shyr, ... Genomics 98 (5), 343-351, 2011 | 25 | 2011 |
| LB01: Risankizumab versus ustekinumab for patients with moderate to severe Crohn’s disease: results from the phase 3b SEQUENCE study L Peyrin-Biroulet, JC Chapman, JF Colombel, F Caprioli, GR D’Haens, ... United European Gastroenterol J 11 (Suppl 8), 2023 | 18 | 2023 |
| Efficacy and safety of selinexor in recurrent glioblastoma. AB Lassman, PY Wen, MJ Van Den Bent, SR Plotkin, AME Walenkamp, ... Journal of Clinical Oncology 37 (15_suppl), 2005-2005, 2019 | 13 | 2019 |
| DOP10 Risankizumab Versus Ustekinumab for the Achievement of Endoscopic Outcomes in Patients With Moderate-to-Severe Crohn’s Disease: Results From the Phase 3b SEQUENCE Trial L Peyrin-Biroulet, P Bossuyt, M Regueiro, S Schreiber, K Gecse, P Irving, ... Journal of Crohn's and Colitis 18 (Supplement_1), i90-i91, 2024 | 9 | 2024 |
| S1 risankizumab versus ustekinumab in patients with moderate to severe Crohn’s Disease: results from the phase 3B SEQUENCE Trial L Peyrin-Biroulet, C Chapman, JF Colombel, F Caprioli, G D’Haens, ... Official journal of the American College of Gastroenterology| ACG 118 (12S), S1, 2023 | 8 | 2023 |
| OP36 Risankizumab Versus Ustekinumab for the Achievement of Clinical Outcomes and Symptom Improvement in Patients With Moderate To Severe Crohn’s Disease: Results From the … MC Dubinsky, G D’Haens, R Atreya, B Abraham, A Armuzzi, ... Journal of Crohn's and Colitis 18 (Supplement_1), i65-i66, 2024 | 6 | 2024 |
| Characterization of tumor mutation burden (TMB) and microsatellite instability (MSI) interplay for gastroesophageal adenocarcinoma (GA) and colorectal carcinoma (CRC). X Huang, JY Tse, A Protopopov, M Russell, D Weeraratne, JE Ring, ... Journal of Clinical Oncology 36 (5_suppl), 22-22, 2018 | 5 | 2018 |
| PHY906 (KD018), an adjuvant based on a 1800-year-old Chinese medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor microenvironment. Sci Rep 2015; 5: 9384 W Lam, Z Jiang, F Guan, X Huang, R Hu, J Wang, S Bussom, SH Liu, ... External Resources Pubmed/Medline (NLM) Crossref (DOI), 0 | 5 | |
| Tumor mutation burden derived from large NGS panel as biomarker for immunotherapy response. D Vuzman, W Powers, X Huang, R Sun, C Eifert, P Cingolani, A Bjonnes, ... Journal of Clinical Oncology 35 (15_suppl), e23077-e23077, 2017 | 4 | 2017 |
| DOP18 Efficacy of risankizumab versus ustekinumab by baseline Crohn’s Disease location: post-hoc analysis of the SEQUENCE head-to-head trial L Peyrin-Biroulet, JF Colombel, G D’Haens, M Dubinsky, Q Cao, K Kligys, ... Journal of Crohn's and Colitis 18 (Supplement_1), i104-i105, 2024 | 2 | 2024 |
| Characterization of biomarkers to immune checkpoint blockade therapy across solid tumors. M Russell, X Huang, D Vuzman, M Lvova, A Pantazi, S Lyle, JY Tse Journal of Clinical Oncology 36 (5_suppl), 26-26, 2018 | 1 | 2018 |
| P0722 Efficacy and Safety of Risankizumab in Patients With Moderate to Severe Crohn’s Disease: Results From the One-Year SEQUENCE Open-Label Long-Term Extension L Peyrin-Biroulet, R Atreya, S Danese, JO Lindsay, JC Chapman, ... Journal of Crohn's and Colitis 19 (Supplement_1), i1407-i1409, 2025 | | 2025 |
| Steroid-sparing effect of risankizumab vs ustekinumab in patients with moderately to severely active Crohn’s disease: Post hoc results from the phase 3b SEQUENCE trial T Raine, S Danese, S Schreiber, X Gao, S Hanauer, J Torres, K Kligys, ... Zeitschrift für Gastroenterologie 62 (09), KV 032, 2024 | | 2024 |
| O23 Risankizumab vs ustekinumab for patients with moderate-to-severe crohn’s disease: results from the phase 3b SEQUENCE study J Lindsay, L Peyrin-Biroulet, JC Chapman, JF Colombel, F Caprioli, ... Gut 73 (Suppl 1), A12-A13, 2024 | | 2024 |
